This contract expires in 84 days (Sep 30, 2026).
BRISTOL-MYERS SQUIBB COMPANY - MAVACAMTEN IS AN OUTPATIENT DRUG USED IN THE TREATMENT OF SPECIFIC TYPES OF CARDIOMYOPATHIES.
Key Details
Description
MAVACAMTEN IS AN OUTPATIENT DRUG USED IN THE TREATMENT OF SPECIFIC TYPES OF CARDIOMYOPATHIES.
Context & Analysis
On Jan 8, 2026, Department of Veterans Affairs obligated $327,534.3 to BRISTOL-MYERS SQUIBB COMPANY for mavacamten is an outpatient drug used in the treatment of specific types of cardiomyopathies.. The award is classified under NAICS 325412 — PHARMACEUTICAL PREPARATION MANUFACTURING and issued as a firm fixed price contract. Competition extent: full and open competition with 1 offer received. Performance is located in MEMPHIS, TN. The contract is scheduled through Sep 30, 2026 — approximately 3 months remaining. This award is one of several similar procurements from Department of Veterans Affairs under NAICS 325412 — related awards are listed below.
Contractor Information
Similar Awards
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
MCKESSON CORPORATION
$1.4B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
MCKESSON CORPORATION
$1.2B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
MCKESSON CORPORATION
$1.1B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
MCKESSON CORPORATION
$1.1B
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
EXELAN PHARMACEUTICALS INC
$5.1M
Stay Updated
Get notified about new opportunities matching your interests.